Gyre Therapeutics Inc
GYRE
查看详细走势图
7.880USD
+0.370+4.93%
收盘 02/06, 16:00（美东）报价延迟15分钟
716.22M总市值
105.86市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+4.93%
5天
-2.60%
1月
+4.10%
6月
+9.60%
今年开始到现在
+11.61%
1年
-34.88%
查看详细走势图
TradingKey Gyre Therapeutics Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Gyre Therapeutics Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名81/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价18.00。中期看，股价处于平稳状态。近一个月，市场表现较强，技术面和基本面综合得分较高，较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Gyre Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Gyre Therapeutics Inc亮点
亮点风险
Gyre Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. F230 is a clinical-stage compound for the treatment of pulmonary arterial hypertension. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product.
业绩高增长
公司营业收入稳步增长，连续3年增长13219.52%
业绩转盈
公司业绩转盈，最新年度盈利美元
估值高估
公司最新PE估值105.86，处于3年历史高位
机构减仓
最新机构持股3.16M股，环比减少11.35%
PRFDX持仓
明星投资者PRFDX持仓，最新持仓市值1.28K
分析师目标
根据
3
位分析师
买入
评级
18.000
目标均价
+128.43%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Gyre Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Gyre Therapeutics Inc简介
Gyre Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. F230 is a clinical-stage compound for the treatment of pulmonary arterial hypertension. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product.
公司代码GYRE
公司Gyre Therapeutics Inc
CEOZhang (Ping)
网址https://www.gyretx.com/
相关品种
